LLY · Eli Lilly and Company

S&P 500 #11 · NYSE

Risiko 4/10 · MODERATE RISK · megacap pharma · $1,221 ▲ 1.93%

Kennzahlen

• Price $1,221
• Market cap $1.09T
• P/E (ttm) 43.38
• Div yield 0.58%
• 52-wk range $623.78 – $1249.45
• Index rank #11 / —

Wichtigste Risiken

• Lofty valuation vs earnings (Shareholders) — HIGH
• GLP-1 competition (Novo, others) (Shareholders) — MED
• Drug pricing / policy pressure (Shareholders) — MED
• Patent cliff & pipeline risk (Shareholders) — LOW

Fazit

Obesity/diabetes drug juggernaut whose weight-loss franchise made it the most valuable healthcare company, on a rich growth multiple.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.